The effectiveness of Radioligand Therapy is rooted in its precise mechanism of action. RLT uses a molecule designed to bind to a specific receptor or antigen on cancer cells. This molecule is chemically linked to a radioactive isotope that emits therapeutic radiation.

Once administered, the radioligand travels through the body and selectively attaches to cancer cells expressing the target receptor. Upon binding, the radioactive component delivers ionizing radiation that damages the DNA of the cancer cell, ultimately leading to cell death. This localized radiation minimizes exposure to healthy tissues.

Different radioactive isotopes are used depending on the treatment goal. Beta-emitting isotopes are commonly used for larger tumors, while alpha emitters deliver high-energy radiation over very short distances, making them suitable for targeting microscopic disease.

The success of this mechanism depends on receptor expression, radioligand stability, and effective internalization by cancer cells. Advances in radiochemistry have improved ligand binding affinity and radioactive payload delivery.

Through this biologically precise mechanism, Radioligand Therapy offers a powerful and selective cancer treatment strategy.